Cargando…

CD19+ B Lymphocytes Are Predictive for Anti-Sars-Cov-2 Vaccination Response in Multiple Myeloma Patients

Introduction: Up to now,reliable results regarding the efficacy of anti-SARS-CoV-2 vaccines in patients with multiple myeloma (MM), especially under current myeloma-directed therapy, are scarcely available. Here, we report an analysis describing the level of post-vaccination antibody titers after th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghandili, Susanne, Schönlein, Martin, Becher, Heiko, Wiessner, Christian, Lütgehetmann, Marc, Schulze zur Wiesch, Julian, Bokemeyer, Carsten, Sinn, Marianne, Leypoldt, Lisa, Weisel, Katja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology. Published by Elsevier Inc. 2021
Materias:	652.Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701540/ http://dx.doi.org/10.1182/blood-2021-149062

Ejemplares similares

The Impact of the COVID-19 Pandemic on Quality of Life in Danish Patients with Multiple Myeloma; Results from an Ongoing Longitudinal National Survey
por: Redder, Louise, et al.
Publicado: (2021)

COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
por: Branagan, Andrew R., et al.
Publicado: (2021)

Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment
por: Van Oekelen, Oliver, et al.
Publicado: (2021)

Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients
por: Stampfer, Samuel D., et al.
Publicado: (2021)

Multiple Myeloma, Clinical Characteristics, and Increased COVID-19 Risk Using Real-World Data
por: Liu, Emily I., et al.
Publicado: (2021)

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic
por: Martínez-López, Joaquín, et al.
Publicado: (2021)

OAB-049: Poor post-vaccination anti-SARS-CoV-2-antibody response in patients with Multiple Myeloma correlates with low CD19+ B-lymphocyte count and anti-CD38 treatment
por: Ghandili, Susanne, et al.
Publicado: (2021)

Inadequate Sars-Cov-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study
por: Fillmore, Nathanael R, et al.
Publicado: (2021)

Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM)
por: Rögnvaldsson, Sæmundur, et al.
Publicado: (2021)

High Humoral Response after Anti-Sars-Cov-2 mRNA-Based Vaccines in Patients with Active Multiple Myeloma (MM) and Relationship with Disease Status/Line of Therapy
por: Mancuso, Katia, et al.
Publicado: (2021)

Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination
por: Terpos, Evangelos, et al.
Publicado: (2021)

Response to COVID-19 Vaccines in Patients Receiving Intensified Post-ASCT Therapy with Daratumumab, Lenalidomide, Bortezomib (Dara-VR) Due to Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) or Primary Plasma Cell Leukemia (pPCL): Exploratory Analysis of the UK Optimum/Muknine Trial
por: Jenner, Matthew W, et al.
Publicado: (2021)

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
por: Ghandili, Susanne, et al.
Publicado: (2021)

Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
por: Ghandili, Susanne, et al.
Publicado: (2021)

COVID-19 in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): An Observational Retrospective Study
por: Sgherza, Nicola, et al.
Publicado: (2021)

Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy
por: Kastritis, Efstathios, et al.
Publicado: (2021)

Neutralizing Antibody Responses Against Sars-Cov-2 in Patients with Plasma Cell Disorders Who Are on Active Treatment after Two Doses of mRNA Vaccination
por: Abdallah, Al-Ola, et al.
Publicado: (2021)

Safety and Tolerability of Sars-Cov-2 Vaccination and Natural History of Infection Among Patients with Castleman Disease
por: Pierson, Sheila K, et al.
Publicado: (2021)

Serological Response to the BNT162b2 mRNA or Chadox-Ncov-19 COVID-19 Vaccine after First and Second Doses in Plasma Cell Disorder Patients: Influence of Host and Disease Factors
por: Chan, Wei Yee, et al.
Publicado: (2021)

The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era
por: Resende Salgado, Lucas, et al.
Publicado: (2018)

MM-219: Outcome of COVID-19 Among Patients with Multiple Myeloma at the Armenian Hematology Center
por: Sahakyan, Lusine, et al.
Publicado: (2021)

Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
por: Harush, Ortal, et al.
Publicado: (2022)

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
por: Sanchez, Larysa, et al.
Publicado: (2021)

PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant
por: Thomas, Melissa, et al.
Publicado: (2023)

VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience
por: Ghandili, Susanne, et al.
Publicado: (2022)

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
por: Usmani, Saad Z., et al.
Publicado: (2022)

Case series: MRD negativity assessment using (11)C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma
por: Ngai, Cheong, et al.
Publicado: (2021)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Front-line treatment of multiple myeloma
por: Cavo, Michele, et al.
Publicado: (2019)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

How I treat relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2020)

How I manage frontline transplant-ineligible multiple myeloma
por: Derudas, Daniele, et al.
Publicado: (2020)

The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma
por: Becnel, Melody R., et al.
Publicado: (2020)

Bone marrow niche in multiple myeloma and its precursor states
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2019)

How I manage frontline transplant-eligible multiple myeloma in Italy
por: Montefusco, Vittorio, et al.
Publicado: (2020)

Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd)
por: Byun, Ja Min, et al.
Publicado: (2020)

Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation
por: Yang, Chen-lu, et al.
Publicado: (2021)

BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis
por: Li, Guang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m7hhr2kmdb9u3pl6uam4iq737k